MEDTECH AGENDA

PANEL: Beyond Seed and Series A: Early-Stage MedTech Start-Up Funding Challenges

The medtech industry presents unique struggles for early-stage start-ups seeking series A funding, which has seen a decline since 2017.

This panel explores the factors contributing to this decline and the hurdles entrepreneurs face when entering the medtech space. 

• How do early-stage medtech start-ups navigate declining Series A funding. 
• How do investors assess the potential for steady returns in medtech start-ups, given the industry's lower yields compared to other sectors? 
• How are investors handling time, capital constraints, and uncertainties related to reimbursement policies for medtech start-ups seeking investments post-commercial success? 

Thom Rasche, Managing Partner, Earlybird  
Esther Richardot Reynal De Saint-Michel, Partner, THENA Capital 
   

PANEL: Advanced Medtech Ventures: Funding Obstacles for Maturing Medtechs 

As medtech companies progress beyond Series C funding, they face a new set of hurdles in securing further investments to fuel their growth and innovation.

From market maturation and regulatory complexities to valuation expectations and achieving sustainable growth, this panel will explore strategies and best practices to overcome funding obstacles and drive success in the rapidly evolving medtech landscape. 

• How do investors assess the potential for sustained growth and market differentiation for late-stage medtech companies 
• How can maturing companies navigate complex regulatory and reimbursement landscapes 
• How do investors view valuation expectations, what approach strikes a balance between attracting investment and demonstrating long-term potential for investors? 

Bhavesh Barot, Operating Partner, Truffle Capital  

PANEL: Beyond the Finish Line: Overcoming Late-Stage HealthTech Investment Barriers 

Late-stage healthtech companies face a number of evolving difficulties from their first series rounds. Overcoming these demands a strong team, effective investor communication, proven execution, and a clear growth strategy for successful funding and realizing their potential.

This panel will look at strategies and best practices to navigate these roadblocks, empowering late-stage healthtech companies to thrive.

• How do investors assess a late-stage healthtech company's readiness for market validation and scalability, and what criteria is considered to evaluate its potential for sustained growth 
• What strategies have successful late-stage healthtech companies employed to navigate complex regulatory landscapes, secure reimbursement, and address financial challenges 
• Examples of effective partnership and collaboration approaches that have proven beneficial companies seeking to expand their market presence and overcome competition 

Jia-Yi Har, Partner, Cathay Capital
Samuel Levy, Founding Partner, Lauxera Capital 
Assaf Barnea, Managing Partner, Sanara Ventures 

Drinks Reception

Close of Investival Showcase

Awards & Gala Dinner
- Separate ticket required
- Find out more